You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR MIRABEGRON

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for MIRABEGRON

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00410514 ↗	A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)	Completed	Astellas Pharma Inc	Phase 2	2006-12-01	This study examined the safety, tolerability, and efficacy of mirabegron (YM178) compared to placebo.
NCT00662909 ↗	A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder	Completed	Astellas Pharma Inc	Phase 3	2008-03-28	The study is intended to test the efficacy, safety and tolerability of two doses of mirabegron against placebo to treat patients with symptoms of overactive bladder
NCT00688688 ↗	Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder	Completed	Astellas Pharma Inc	Phase 3	2008-04-25	The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for MIRABEGRON

Condition Name

Chart
Table

Condition Name for MIRABEGRON
Intervention	Trials
Overactive Bladder	37
Urinary Bladder, Overactive	14
Healthy Subjects	13
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for MIRABEGRON
Intervention	Trials
Urinary Bladder, Overactive	70
Syndrome	8
Urologic Diseases	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for MIRABEGRON

Trials by Country

Map
Table

Trials by Country for MIRABEGRON
Location	Trials
United States	334
Canada	60
Japan	20
Germany	20
Korea, Republic of	17
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for MIRABEGRON
Location	Trials
California	18
Maryland	15
Florida	14
New York	13
Washington	12
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for MIRABEGRON

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for MIRABEGRON
Clinical Trial Phase	Trials
Phase 4	37
Phase 3	21
Phase 2/Phase 3	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for MIRABEGRON
Clinical Trial Phase	Trials
Completed	86
Recruiting	21
Not yet recruiting	15
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for MIRABEGRON

Sponsor Name

Chart
Table

Sponsor Name for MIRABEGRON
Sponsor	Trials
Astellas Pharma Inc	39
Astellas Pharma Europe B.V.	14
Mansoura University	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for MIRABEGRON
Sponsor	Trials
Other	109
Industry	80
NIH	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.